Investors who lost money on MacroGenics, Inc.(MGNX) should contact The Gross Law Firm about pending Class Action - MGNX

Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) is facing a class action lawsuit due to allegations of material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1] Group 1 - The class period for the alleged misrepresentations is from March 7, 2024, to May 9, 2024 [1] - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously stated, resulting in a stock price drop of $11.36 per share [1] - Shareholders who purchased MGNX shares during the class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1][2] Group 2 - The deadline for shareholders to register for the class action is September 24, 2024 [2] - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - There is no cost or obligation for shareholders to participate in the case [2] Group 3 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]